According to the Boston Globe, the acquisition is projected to generate about $200 million in revenue this year.
Lumenis sells Surgical Business to Boston Scientific (NYSE: BSX) for $1.07 billion
Baring Private Equity Asia (BPEA) and Lumenis announced today that they have entered into a definitive agreement to sell the Lumenis Surgical Business to Boston Scientific (NYSE: BSX) in a transaction valued at $1.07 bln, subject to closing adjustments. The Surgical Business includes laser and fibers solutions for minimally-invasive surgical procedures in Urology and ENT.